These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
472 related articles for article (PubMed ID: 28466200)
1. MYC and RAF: Key Effectors in Cellular Signaling and Major Drivers in Human Cancer. Stefan E; Bister K Curr Top Microbiol Immunol; 2017; 407():117-151. PubMed ID: 28466200 [TBL] [Abstract][Full Text] [Related]
2. Mechanical signals control SOX-9, VEGF, and c-Myc expression and cell proliferation during inflammation via integrin-linked kinase, B-Raf, and ERK1/2-dependent signaling in articular chondrocytes. Perera PM; Wypasek E; Madhavan S; Rath-Deschner B; Liu J; Nam J; Rath B; Huang Y; Deschner J; Piesco N; Wu C; Agarwal S Arthritis Res Ther; 2010; 12(3):R106. PubMed ID: 20509944 [TBL] [Abstract][Full Text] [Related]
3. Complementation of defective colony-stimulating factor 1 receptor signaling and mitogenesis by Raf and v-Src. Aziz N; Cherwinski H; McMahon M Mol Cell Biol; 1999 Feb; 19(2):1101-15. PubMed ID: 9891045 [TBL] [Abstract][Full Text] [Related]
4. K-Ras and B-Raf oncogenes inhibit colon epithelial polarity establishment through up-regulation of c-myc. Magudia K; Lahoz A; Hall A J Cell Biol; 2012 Jul; 198(2):185-94. PubMed ID: 22826122 [TBL] [Abstract][Full Text] [Related]
5. Diminished WNT -> β-catenin -> c-MYC signaling is a barrier for malignant progression of BRAFV600E-induced lung tumors. Juan J; Muraguchi T; Iezza G; Sears RC; McMahon M Genes Dev; 2014 Mar; 28(6):561-75. PubMed ID: 24589553 [TBL] [Abstract][Full Text] [Related]
6. c-Myc is Required for BRAF Qu Y; Yang Q; Liu J; Shi B; Ji M; Li G; Hou P Theranostics; 2017; 7(7):2092-2107. PubMed ID: 28656062 [No Abstract] [Full Text] [Related]
7. Targeting c-MYC through Interference with NAMPT and SIRT1 and Their Association to Oncogenic Drivers in Murine Serrated Intestinal Tumorigenesis. Brandl L; Zhang Y; Kirstein N; Sendelhofert A; Boos SL; Jung P; Greten F; Rad R; Menssen A Neoplasia; 2019 Oct; 21(10):974-988. PubMed ID: 31442917 [TBL] [Abstract][Full Text] [Related]
8. MYC Analysis in Cancer and Evolution. Hartl M; Bister K Methods Mol Biol; 2021; 2318():87-117. PubMed ID: 34019288 [TBL] [Abstract][Full Text] [Related]
9. MYC synergizes with activated BRAFV600E in mouse lung tumor development by suppressing senescence. Tabor V; Bocci M; Alikhani N; Kuiper R; Larsson LG Cancer Res; 2014 Aug; 74(16):4222-9. PubMed ID: 24934810 [TBL] [Abstract][Full Text] [Related]
10. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers. Roskoski R Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796 [TBL] [Abstract][Full Text] [Related]
11. Dual functions for OVAAL in initiation of RAF/MEK/ERK prosurvival signals and evasion of p27-mediated cellular senescence. Sang B; Zhang YY; Guo ST; Kong LF; Cheng Q; Liu GZ; Thorne RF; Zhang XD; Jin L; Wu M Proc Natl Acad Sci U S A; 2018 Dec; 115(50):E11661-E11670. PubMed ID: 30478051 [TBL] [Abstract][Full Text] [Related]
12. C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells. Zhuang D; Mannava S; Grachtchouk V; Tang WH; Patil S; Wawrzyniak JA; Berman AE; Giordano TJ; Prochownik EV; Soengas MS; Nikiforov MA Oncogene; 2008 Nov; 27(52):6623-34. PubMed ID: 18679422 [TBL] [Abstract][Full Text] [Related]
13. Crosstalk between oncogenic MYC and noncoding RNAs in cancer. Tu R; Chen Z; Bao Q; Liu H; Qing G Semin Cancer Biol; 2021 Oct; 75():62-71. PubMed ID: 33160022 [TBL] [Abstract][Full Text] [Related]
14. Functional interactions among members of the MAX and MLX transcriptional network during oncogenesis. Diolaiti D; McFerrin L; Carroll PA; Eisenman RN Biochim Biophys Acta; 2015 May; 1849(5):484-500. PubMed ID: 24857747 [TBL] [Abstract][Full Text] [Related]
15. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Hatzivassiliou G; Song K; Yen I; Brandhuber BJ; Anderson DJ; Alvarado R; Ludlam MJ; Stokoe D; Gloor SL; Vigers G; Morales T; Aliagas I; Liu B; Sideris S; Hoeflich KP; Jaiswal BS; Seshagiri S; Koeppen H; Belvin M; Friedman LS; Malek S Nature; 2010 Mar; 464(7287):431-5. PubMed ID: 20130576 [TBL] [Abstract][Full Text] [Related]
16. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453 [TBL] [Abstract][Full Text] [Related]
17. Parthenolide suppresses non-small cell lung cancer GLC-82 cells growth via B-Raf/MAPK/Erk pathway. Lin M; Bi H; Yan Y; Huang W; Zhang G; Zhang G; Tang S; Liu Y; Zhang L; Ma J; Zhang J Oncotarget; 2017 Apr; 8(14):23436-23447. PubMed ID: 28423582 [TBL] [Abstract][Full Text] [Related]
18. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer. Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210 [TBL] [Abstract][Full Text] [Related]
19. Raf: a strategic target for therapeutic development against cancer. Beeram M; Patnaik A; Rowinsky EK J Clin Oncol; 2005 Sep; 23(27):6771-90. PubMed ID: 16170185 [TBL] [Abstract][Full Text] [Related]